Willingsford has developed the Micropore Particle Technology – MPPT.

This is a passive immune therapy to combat wound infections and promote healing of wounds.

It preserves and balances the microbiome and has shown 60% quicker clinical effects than antibiotics and antiseptics.

Willingsford manufactures two products based on MPPT for use in the healing of wounds:


Acapsil approved in the EU for use in humans.


SertaSil approved for use in animals.

Please visit the product website of your interest.

Products to support our MPPT wound devices are under current development.

Also, new early stage R&D projects have been initiated.